Market Introduction
Anaphylaxis is an allergic reaction that can further lead to a fatal condition known as anaphylactic shock. Anaphylaxis occurs when the patient's body reacts to a foreign substance and produces a high amount of histamine that triggers an inflammatory response. It is a severe, life threatening allergic reaction marked by indications such as swallowing and breathing difficulties, skin itching, and lowering blood pressure.
Thus, the rising incidence of anaphylaxis is expected to create a significant demand for anaphylaxis treatment in the coming years, which is further anticipated to drive the anaphylaxis treatment market.
Countries in the Middle East have also widely affected the socio-economic condition by the COVID–19 pandemic. However, the countries have wisely reacted to the COVID–19 pandemic to avoid the spread of infection. Similar to other regions, lockdown and social distancing were imposed, which has impaired these trends hindering access to work, regular income, payments, fairs, schools, and healthcare. Therefore, it is expected the countries have undergone huge losses and are still trying to recover them. Due to the less developed economies majority of the countries are depended on the suppliers of medical devices. In addition, there is high uncertainty of the spread of COVID-19 in Africa and other low-income countries such as Cameroon, Egypt, Algeria, Morocco, South Africa, Togo, Nigeria, Senegal, and Tunisia. Due to a widespread outbreak of COVID-19 in Africa, has led to disruption in healthcare services. However, the anaphylaxis treatment market in this pandemic is growing due to the increasing awareness about treatments of asthma and allergic diseases linked to viral infection in the region.
Market Overview and Dynamics
The Anaphylaxis treatment market in Middle East and Africa is expected to grow from US$ 52.2 million in 2021 to US$ 87.1 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2021 to 2028. Novel drug delivery systems support improved drug potency and controlled drug release, along with imparting a sustained therapeutic effect for reliable safety. Many drugs have a maximum concentration range for maximum benefit, and concentrations above or below can be toxic or produce no medicinal use. Furthermore, various drug delivery and drug targeting systems are explained to have a capability of minimizing drug degradation as well as preventing harmful side effects. The intramuscular injection of epinephrine is normally underutilized when anaphylaxis occurs, mainly due to unavailability or unaffordability. Drugs provide the convenience of a wide range of pain-free multiple doses, particularly for children, if required, for out-of-hospital emergency treatment of anaphylaxis.
Key Market Segments
In terms of medication type, the epinephrine segment accounted for the largest share of the Middle East and Africa anaphylaxis treatment market in 2020. In terms of route of administration, the parenteral segment accounted for the largest share of the Middle East and Africa anaphylaxis treatment market in 2020. In terms of allergy type, the food allergy segment accounted for the largest share of the Middle East and Africa anaphylaxis treatment market in 2020. In terms of distribution channel, the retail pharmacies segment held a larger market share of the anaphylaxis treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the anaphylaxis treatment market in Middle East and Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Amneal Pharmaceuticals Inc., Mylan N.V., Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó.
Reasons to buy report
- To understand the Middle East and Africa anaphylaxis treatment market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East and Africa anaphylaxis treatment market
- Efficiently plan M&A and partnership deals in Middle East and Africa Anaphylaxis treatment market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East and Africa Anaphylaxis treatment market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Middle East and Africa region.
MIDDLE EAST AND AFRICA ANAPHYLAXIS TREATMENT MARKET SEGMENTATION
By Medication Type
- Epinephrine
- Antihistamines
- Steroids
- Beta-Agonist
- Others
By Route of Administration
- Parenteral
- Oral
- Others
By Allergy Type
- Food Allergy
- Medications
- Insect Stings
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
-
Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Companies Mentioned
- Amneal Pharmaceuticals Inc.
- Mylan N.V.
- Abbott
- Pfizer Inc.
- Glaxosmithkline Plc.,
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ALK-ABELLó
Middle East and Africa Anaphylaxis Treatment Market Strategic Insights
Middle East and Africa Anaphylaxis Treatment Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 52.2 Million |
| Market Size by 2028 | US$ 87.1 Million |
| CAGR (2021 - 2028) | 7.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Medication Type
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Anaphylaxis Treatment Market Country and Regional Insights
